Abstract
Worcester Foundation for Experimental Biology, Shrewsbury, Massachusetts 01545, U.S.A. (Received 8 November 1974) Oestrogens have been found to stimulate prolactin release in the rat (Chen & Meites, 1970) and increases in prolactin in the circulation have been reported to be essential for the maintenance and growth of dimethylbenz(α)anthracene (DMBA)-induced rat mammary carcinomata (Pearson, Molina, Butler, Llerena & Nasr, 1972). Non-steroidal anti-oestrogens retard the growth of DMBA-induced rat mammary carcinoma (Schulz, Haselmayer & Hölzel, 1971; Terenius, 1971) and one such compound nafoxidine (U-11, 100A) has been shown to inhibit oestrogen-stimulated prolactin release in rats (Heuson, Waelbroeck, Legros, Gallez, Robyn & L'Hermite, 1971–72) thereby suggesting a mechanism for antitumour activity which may occur simultaneously with tumour oestrogen receptor blockade (Terenius, 1971). The present investigation was undertaken to determine whether other anti-oestrogens could control oestrogen-stimulated prolactin release. The non-steroidal anti-oestrogens ICI 46,474 (tamoxifen, trade name Nolvadex, trans 1-(ρ-β-dimethylaminoethoxyphenyl)-1,2-diphenyl but-1-ene) and MER 25 (ethamoxytriphetol,
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call